Rebecca L. Brouillette
Sherbrooke, QC J1H5N4, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
A neurotensin receptor type 1-derived pepducin acts as a biased allosteric modulator to regulate target receptor function.
Journal: Acta pharmaceutica Sinica. B
Published: August 01, 2025
A lipidated peptide derived from the C-terminal tail of the vasopressin 2 receptor shows promise as a new β-arrestin inhibitor.
Journal: Pharmacological research
Published: August 23, 2024
Design, Synthesis, and In Vitro Characterization of Proteolytically-Stable Opioid-Neurotensin Hybrid Peptidomimetics.
Journal: ACS pharmacology & translational science
Published: April 23, 2024
Discovery of a CCR2-targeting pepducin therapy for chronic pain.
Journal: Pharmacological research
Published: January 26, 2024
Structural insight into apelin receptor-G protein stoichiometry.
Journal: Nature structural & molecular biology
Published: March 10, 2022
The P2Y6 receptor signals through Gαq /Ca2+ /PKCα and Gα13 /ROCK pathways to drive the formation of membrane protrusions and dictate cell migration.
Journal: Journal of cellular physiology
Published: January 09, 2020
Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog.
Journal: European journal of pharmacology
Published: December 20, 2019
Last Updated: 09/26/2026